These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6431104)

  • 1. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.
    Jones CD; Jevnikar MG; Pike AJ; Peters MK; Black LJ; Thompson AR; Falcone JF; Clemens JA
    J Med Chem; 1984 Aug; 27(8):1057-66. PubMed ID: 6431104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
    Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
    Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
    Wakeling AE; Valcaccia B
    J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
    Black LJ; Jones CD; Falcone JF
    Life Sci; 1983 Feb; 32(9):1031-6. PubMed ID: 6827921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
    Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
    Neubauer BL; Biser P; Jones CD; Mariotti A; Hoover DM; Thornton T; Thornton MO; Goode RL
    Prostate; 1989; 15(3):273-86. PubMed ID: 2531383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
    Clemens JA; Bennett DR; Black LJ; Jones CD
    Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
    Gauthier S; Caron B; Cloutier J; Dory YL; Favre A; Larouche D; Mailhot J; Ouellet C; Schwerdtfeger A; Leblanc G; Martel C; Simard J; Mérand Y; Bélanger A; Labrie C; Labrie F
    J Med Chem; 1997 Jul; 40(14):2117-22. PubMed ID: 9216828
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs.
    Kym PR; Anstead GM; Pinney KG; Wilson SR; Katzenellenbogen JA
    J Med Chem; 1993 Nov; 36(24):3910-22. PubMed ID: 8254621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
    Jordan VC; Gosden B
    Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
    di Salle E; Zaccheo T; Ornati G
    J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
    Hartmann RW; Heindl A; Schneider MR; Schönenberger H
    J Med Chem; 1986 Mar; 29(3):322-8. PubMed ID: 3005573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes.
    Hartmann RW; Schwarz W; Heindl A; Schönenberger H
    J Med Chem; 1985 Sep; 28(9):1295-301. PubMed ID: 2993619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.